Kiley Juergens Wealth Management LLC Takes Position in AbbVie Inc. $ABBV

Kiley Juergens Wealth Management LLC acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) during the first quarter, Holdings Channel.com reports. The institutional investor acquired 7,295 shares of the company’s stock, valued at approximately $1,587,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Chelsea Counsel Co. acquired a new stake in shares of AbbVie in the 3rd quarter valued at $26,000. Litman Gregory Wealth Management LLC bought a new stake in shares of AbbVie during the 4th quarter worth $28,000. Imprint Wealth LLC boosted its stake in AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares in the last quarter. Westend Capital Management LLC acquired a new stake in AbbVie in the fourth quarter valued at about $29,000. Finally, IFC & Insurance Marketing Inc. bought a new position in AbbVie in the fourth quarter valued at about $31,000. Institutional investors own 70.23% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie received a European Commission approval for TEPKINLY (epcoritamab) plus lenalidomide and rituximab to treat relapsed or refractory follicular lymphoma. The approval expands the drug’s reach in Europe and supports AbbVie’s oncology growth story. Article: AbbVie Announces TEPKINLY approval by the European Commission
• Positive Sentiment: Cantor Fitzgerald raised its price target on AbbVie to $265 and kept an overweight rating, signaling continued analyst confidence in the stock’s upside. Article: AbbVie price target raised by Cantor Fitzgerald
• Neutral Sentiment: AbbVie is also getting some investor focus ahead of its upcoming quarterly report, with analysts watching whether Skyrizi and Rinvoq can offset continued pressure from Humira declines. Article: Will Immunology Franchise Aid AbbVie’s Upcoming Q2 Results?
• Negative Sentiment: AbbVie cut its second-quarter 2026 EPS guidance to $3.57-$3.61, below the consensus estimate of $3.77, which could pressure shares. FY 2026 EPS guidance was also lowered to $13.91-$14.11 versus the Street’s $14.25 forecast.

Analyst Ratings Changes

A number of research firms have recently commented on ABBV. Guggenheim reissued a “buy” rating and issued a $249.00 target price on shares of AbbVie in a report on Friday, May 1st. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price on the stock in a research report on Thursday, April 30th. Piper Sandler reiterated an “overweight” rating and set a $298.00 price target on shares of AbbVie in a report on Tuesday, June 23rd. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $256.67.

AbbVie Stock Performance

Shares of ABBV stock traded up $2.96 on Tuesday, hitting $257.71. The company had a trading volume of 1,294,593 shares, compared to its average volume of 7,172,942. AbbVie Inc. has a twelve month low of $184.63 and a twelve month high of $261.64. The stock’s 50-day moving average is $221.27 and its two-hundred day moving average is $220.47. The firm has a market cap of $455.33 billion, a P/E ratio of 126.95, a P/E/G ratio of 0.86 and a beta of 0.30.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same period last year, the company posted $2.46 EPS. The business’s quarterly revenue was up 12.4% on a year-over-year basis. Equities research analysts predict that AbbVie Inc. will post 14.28 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is presently 340.89%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.